Skip to main content
Top
Gepubliceerd in: Quality of Life Research 10/2018

18-06-2018

Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Auteurs: Rebecca Mercieca-Bebber, Douglas Williams, Margaret-Ann Tait, Jessica Roydhouse, Lucy Busija, Chindhu Shunmuga Sundaram, Michelle Wilson, Ailsa Langford, Claudia Rutherford, Natasha Roberts, Madeleine King, Elisabeth Vodicka, Beth Devine, the International Society for Quality of Life Research (ISOQOL)

Gepubliceerd in: Quality of Life Research | Uitgave 10/2018

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Aims

It is important to understand the number, types and regions of trials that include patient-reported outcomes (PROs) to appreciate how patient experiences have been considered in studies of health and interventions. Twenty-seven percent of trials registered with ClinicalTrials.gov (2007–2013) included PROs; however, a regional breakdown was not provided and no reviews have been conducted of the Australia New Zealand Clinical Trials Registry (ANZCTR). We aimed to identify trials registered with ANZCTR with PRO endpoints and describe their characteristics.

Methods

ANZCTR was systematically searched from inception (2005) to 31 March 2017 for trials with PRO endpoints. Search terms included PRO measures listed in Patient-Reported Outcomes Quality of Life Instrument Database and Grid-Enabled Measures, as well as generic PRO terms (e.g. “quality of life” (QOL)). Trial endpoints were individually coded using an established framework to identify trials with PROs for the analysis.

Results

Of 13,666 registered trials, 6168 (45.1%) included a PRO. The proportion of studies including PROs increased between 2006 and 2016 (r = 0.74, p = 0.009). Among the 6168 trials, there were 17,961 individual PRO endpoints, including symptoms/functional outcomes/condition-specific QOL (65.6%), generic QOL (13.2%), patient-reported experiences (9.9%), patient-reported behaviours (7.9%). Mental health was the most common category (99.8% included PROs), followed by physical medicine/rehabilitation (65.6%), musculoskeletal (63.5%), public health (63.1%), and cancer (54.2%).

Discussion

Our findings suggest growing use of PROs in the assessment of health and interventions in ANZ. Our review identifies trial categories with limited patient-reported information and provides a basis for future work on the impact of PRO findings in clinical care.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
2.
go back to reference Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blumle, A., Tomonaga, Y., et al. (2015). Planning and reporting of quality-of-life outcomes in cancer trials. The Annals of Oncology, 26(9), 1966–1973.CrossRefPubMed Schandelmaier, S., Conen, K., von Elm, E., You, J. J., Blumle, A., Tomonaga, Y., et al. (2015). Planning and reporting of quality-of-life outcomes in cancer trials. The Annals of Oncology, 26(9), 1966–1973.CrossRefPubMed
3.
go back to reference Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. The Lancet, 374(9683), 86–89.CrossRef Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. The Lancet, 374(9683), 86–89.CrossRef
4.
go back to reference Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., et al. (2014). Reducing waste from incomplete or unusable reports of biomedical research. The Lancet, 383(9913), 267–276.CrossRef Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., et al. (2014). Reducing waste from incomplete or unusable reports of biomedical research. The Lancet, 383(9913), 267–276.CrossRef
7.
go back to reference Zarin, D. A., Tse, T., Williams, R. J., & Rajakannan, T. (2017). Update on trial registration 11 years after the ICMJE policy was established. New England Journal of Medicine, 376(4), 383–391.CrossRefPubMed Zarin, D. A., Tse, T., Williams, R. J., & Rajakannan, T. (2017). Update on trial registration 11 years after the ICMJE policy was established. New England Journal of Medicine, 376(4), 383–391.CrossRefPubMed
9.
go back to reference Watson, E. K., Firman, D. W., Baade, P. D., & Ring, I. (1996). Telephone administration of the SF-36 health survey: Validation studies and population norms for adults in Queensland. Australian and New Zealand Journal of Public Health, 20(4), 359–363.CrossRefPubMed Watson, E. K., Firman, D. W., Baade, P. D., & Ring, I. (1996). Telephone administration of the SF-36 health survey: Validation studies and population norms for adults in Queensland. Australian and New Zealand Journal of Public Health, 20(4), 359–363.CrossRefPubMed
10.
go back to reference Australian New Zealand Clinical Trials Registry. ANZCTR data field explanation. 2017. Australian New Zealand Clinical Trials Registry. ANZCTR data field explanation. 2017.
13.
go back to reference Ahmed, S., Berzon, R. A., Revicki, D. A., Lenderking, W. R., Moinpour, C. M., Basch, E., et al. (2012). The use of patient-reported outcomes (PRO) within comparative effectiveness research: Implications for clinical practice and health care policy. Medical Care, 50(12), 1060–1070.CrossRefPubMed Ahmed, S., Berzon, R. A., Revicki, D. A., Lenderking, W. R., Moinpour, C. M., Basch, E., et al. (2012). The use of patient-reported outcomes (PRO) within comparative effectiveness research: Implications for clinical practice and health care policy. Medical Care, 50(12), 1060–1070.CrossRefPubMed
14.
go back to reference Scoggins, J. F., & Patrick, D. L. (2009). The use of patient-reported outcomes instruments in registered clinical trials: Evidence from ClinicalTrials.gov. Contemporary Clinical Trials, 30(4), 289–292.CrossRefPubMedPubMedCentral Scoggins, J. F., & Patrick, D. L. (2009). The use of patient-reported outcomes instruments in registered clinical trials: Evidence from ClinicalTrials.gov. Contemporary Clinical Trials, 30(4), 289–292.CrossRefPubMedPubMedCentral
15.
go back to reference Calvert, M., Kyte, D., Mercieca-Bebber, R., et al. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The spirit-pro extension. JAMA, 319(5), 483–494.CrossRefPubMed Calvert, M., Kyte, D., Mercieca-Bebber, R., et al. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The spirit-pro extension. JAMA, 319(5), 483–494.CrossRefPubMed
16.
go back to reference Brundage, M., Blazeby, J., Revicki, D., Bass, B., de Vet, H., Duffy, H., et al. (2013). Patient-reported outcomes in randomized clinical trials: Development of ISOQOL reporting standards. Quality of Life Research, 22(6), 1161–1175.CrossRefPubMed Brundage, M., Blazeby, J., Revicki, D., Bass, B., de Vet, H., Duffy, H., et al. (2013). Patient-reported outcomes in randomized clinical trials: Development of ISOQOL reporting standards. Quality of Life Research, 22(6), 1161–1175.CrossRefPubMed
17.
go back to reference Calvert, M., Blazeby, J., Altman, D. G., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT-PRO extension. JAMA, 309(8), 814–822.CrossRefPubMed Calvert, M., Blazeby, J., Altman, D. G., et al. (2013). Reporting of patient-reported outcomes in randomized trials: The CONSORT-PRO extension. JAMA, 309(8), 814–822.CrossRefPubMed
18.
go back to reference European Medicines Agency. (2016). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: The use of patient-reported outcome (PRO) measures in oncology studies. London: European Medicines Agency. European Medicines Agency. (2016). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: The use of patient-reported outcome (PRO) measures in oncology studies. London: European Medicines Agency.
19.
go back to reference Brodke, D. J., Saltzman, C. L., & Brodke, D. S. (2016). PROMIS for orthopaedic outcomes measurement. The Journal of the American Academy of Orthopaedic Surgeons, 24(11), 744–749.CrossRefPubMed Brodke, D. J., Saltzman, C. L., & Brodke, D. S. (2016). PROMIS for orthopaedic outcomes measurement. The Journal of the American Academy of Orthopaedic Surgeons, 24(11), 744–749.CrossRefPubMed
20.
go back to reference Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573.CrossRefPubMed Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573.CrossRefPubMed
21.
go back to reference Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., et al. (2016). Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. Journal of Clinical Oncology, 34(24), 2925–2934.CrossRefPubMed Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., et al. (2016). Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. Journal of Clinical Oncology, 34(24), 2925–2934.CrossRefPubMed
Metagegevens
Titel
Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)
Auteurs
Rebecca Mercieca-Bebber
Douglas Williams
Margaret-Ann Tait
Jessica Roydhouse
Lucy Busija
Chindhu Shunmuga Sundaram
Michelle Wilson
Ailsa Langford
Claudia Rutherford
Natasha Roberts
Madeleine King
Elisabeth Vodicka
Beth Devine
the International Society for Quality of Life Research (ISOQOL)
Publicatiedatum
18-06-2018
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 10/2018
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-018-1921-5

Andere artikelen Uitgave 10/2018

Quality of Life Research 10/2018 Naar de uitgave